Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation site inhibitor YY201 successfully completed dual submissions in China and US
Recently, YY201, a STAT3 dual phosphorylation site inhibitor independently developed by Yuyao Biotech, was approved by the US FDA and agreed to conduct Phase I clinical studies for malignant hematological tumors. This is another milestone after YY201 IND was approved by China's NMPA in July 2023. It is also an important step for Yuyao Biotech to move towards globalization and international development with its independently built first-class technology platform and leading product pipeline. Learn more about Medicilon's STAT3-targeted Drugs R&D Services. Shanghai Medicilon Inc. (Medicilon), as a partner of Yuyao Biotech, provided YY201 with pharmaceutical research services (including APIs and preparations), preclinical research services (including efficacy, pharmacokinetics, safety evaluation), and IND application services, which helped YY201 successfully complete dual submissions in China and US. Tackle the most cutting-edge new drug research and development techn...